Trials / Recruiting
RecruitingNCT05556603
AssesSment of Early-deteCtion basEd oN liquiD Biopsy in PANCEATIC Cancer (ASCEND-PANCREATIC)
Pancreatic Cancer Detection by Liquid Biopsy in Peripheral Blood: A Prospective Study
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 7,062 (estimated)
- Sponsor
- Ruijin Hospital · Academic / Other
- Sex
- All
- Age
- 40 Years – 75 Years
- Healthy volunteers
- Accepted
Summary
ASCEND-PANCREATIC is a prospective, multi-omics, observational study aimed at early detecting pancreatic cancer by combined assays for biomarkers of cfDNA methylation, circulating tumor DNA (ctDNA) mutation, serum protein markers and blood miRNA markers, in which of 7,062 participants will be enrolled. The development and validation of the model will be conducted in participants with early stage cancers or benign diseases, along with healthy individuals. The performance of the pancreatic cancer detection test will be evaluated in participants with high risk of pancreatic cancer.
Conditions
Timeline
- Start date
- 2022-12-28
- Primary completion
- 2029-06-30
- Completion
- 2029-12-31
- First posted
- 2022-09-27
- Last updated
- 2023-05-06
Locations
3 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05556603. Inclusion in this directory is not an endorsement.